Indian drugmakers fret over FDA crackdown; Lanxess expands Saltigo site;

> Specialty chemicals company Lanxess is investing about €60 million ($65 million) to expand a Saltigo site in Leverkusen, Germany. Report

> Indian drugmakers discussed FDA concerns at a meeting recently, with experts acknowledging that some companies need to improve operations to avoid getting Form 483s from the agency. Report

> CDMO Lonza argues the industry is lagging in its use of electronic documentation for quality control. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

Pricing controversies shouldn't overshadow Phlow's promise to provide low-cost drugs to address COVID-19, says the CEO of partner Civica Rx.